^
    2ms
    Intrahepatic targeting and sustained release of a Toll like receptor 8 agonist enhances hepatocellular carcinoma therapy. (PubMed, J Control Release)
    We developed a CD47-mimetic self-peptide-modified liposomal system that targets SIRPα on Kupffer cells and delivers the TLR8 agonist ZG0895, currently in clinical trials in the U.S. and China...Importantly, this phagocytosis inhibition establishes a spatiotemporal window that facilitates co-delivery of doxorubicin (DOX) liposomes to HCC cells via GLUT1-mediated targeting, resulting in synergistic immunochemotherapeutic effects. This dual modulation strategy improves targeting precision, treatment durability, and therapeutic synergy, offering a unique intrahepatic approach that addresses key challenges in HCC management and accelerates the clinical translation of TLR8 agonist-based nanomedicines.
    Journal
    |
    TLR8 (Toll Like Receptor 8) • SIRPA (Signal Regulatory Protein Alpha) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    ZG0895
    almost2years
    Study of ZG0895.HCl in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Not yet recruiting --> Recruiting | Initiation date: Dec 2023 --> Aug 2023
    Enrollment open • Trial initiation date • Metastases
    |
    ZG0895
    2years
    Study of ZG0895.HCl in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Initiation date: Jul 2023 --> Dec 2023
    Trial initiation date • Metastases
    |
    ZG0895
    over2years
    Study of ZG0895.HCl in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, Suzhou Zelgen Biopharmaceuticals Co.,Ltd
    New P1 trial • Metastases
    |
    ZG0895